Cirius Therapeutics
Grand Rapids, US · Founded 2015 · Delaware corporation · 2 known investors
Find your way into Cirius Therapeutics
174 people in our graph share verified history with the Cirius Therapeutics team — schools, employers, funds. One of them is your warm intro.
Arnon Dinurunlockedknows Brian Farmer · together at Texas McCombs School of Business (overlapped)
×3knows the team · via Texas McCombs School of Business
knows the team · via Inipharm
×2knows the team · via Frazier Healthcare Partners
×5knows the team · via Trinity University
Cirius Therapeutics is a clinical-stage pharmaceutical company developing therapies for patients with chronic metabolic diseases driven by insulin resistance, including Type 2 Diabetes and obesity.
Founders & leadership
JC
Jerry CallahanExecutive
BF
RB
Robert BalteraExecutive
HD
Howard DittrichExecutive
Board
MJ
Michael JandernoaBoard director
MO
Mark OlesnavageBoard director
DV
David Van AndelBoard director
NK
Nilesh KumarBoard director
DE
RZ
Robert ZerbeBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$49.6M disclosed across 6 rounds · 2017–2025
▶$800KraisedOct 2025 · 22 investors · BiotechnologyRule 506(b)
▶$800KraisedOct 2025 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael JandernoaDirector
- Robert A BeardsleyExecutive Officer
- Robert ZerbeDirector
- David Van AndelDirector
- Jerry CallahanExecutive Officer
- Offering amount
- $1.2M
- Amount sold
- $800K
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedOct 2024 · 22 investors · BiotechnologyRule 506(b)
▶$1MraisedOct 2024 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David Van AndelDirector
- Michael JandernoaDirector
- Mark OlesnavageExecutive Officer
- Robert BeardsleyExecutive Officer
- Jerry CallahanExecutive Officer
- Robert ZerbeDirector
- Offering amount
- $1.6M
- Amount sold
- $1M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedAug 2024 · 24 investors · BiotechnologyRule 506(b)
▶$1.3MraisedAug 2024 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael JandernoaDirector
- Jerry CallahanExecutive Officer
- Mark OlesnavageExecutive Officer
- David Van AndelDirector
- Robert ZerbeDirector
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedMay 2019 · 29 investors · Other Health CareRule 506(b)
▶$7.5MraisedMay 2019 · 29 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Elaine SunDirector
- Baltera BobExecutive Officer, Director
- Daniel Estes, Ph.D.Director
- Michael JandernoaDirector
- Nilesh Kumar, Ph.D.Director
- David Van AndelDirector
- Robert Zerbe, M.D.Director
- Dennis Fenton, Ph.D.Director
- Brian FarmerExecutive Officer
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$9MraisedAug 2018 · 30 investors · Other Health CareRule 506(b)
▶$9MraisedAug 2018 · 30 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Nilesh Kumar, Ph.D.Director
- Baltera BobExecutive Officer, Director
- Robert Zerbe, M.D.Director
- Brian FarmerExecutive Officer
- David Van AndelDirector
- Michael JandernoaDirector
- Dennis Fenton, Ph.D.Director
- Daniel Estes, Ph.D.Director
- Offering amount
- $9M
- Amount sold
- $9M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$30MraisedApr 2017 · 21 investors · BiotechnologyRule 506(b)
▶$30MraisedApr 2017 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian FarmerExecutive Officer
- Nilesh KumarDirector
- Robert BalteraExecutive Officer, Director
- David Van AndelDirector
- Howard DittrichExecutive Officer
- Daniel EstesDirector
- Michael JandernoaDirector
- Robert ZerbeDirector
- Offering amount
- $40.5M
- Amount sold
- $30M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapBioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Amicus Therapeutics8 shared keywordsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
Sitryx7 shared keywordsSitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism. It has entered a global licensing and research collaboration with Eli Lilly and Company.
Nurix Therapeutics6 shared keywordsNurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.
Cyrusbio5 shared keywordsCyrus operates a protein engineering platform that combines AI and Rosetta computational design methods with a biochemistry lab performing large-scale deep mutagenesis scanning, protein stabilization, immunogenicity reduction, and affinity/specificity tuning. It designs and re-engineers biologic therapeutics, working on internal and partnered drug programs including COVID assets and gene therapy candidates.
Companies competing with Cirius Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Cirius Therapeutics do?
- Cirius Therapeutics is a clinical-stage pharmaceutical company developing therapies for patients with chronic metabolic diseases driven by insulin resistance, including Type 2 Diabetes and obesity.
- Who are Cirius Therapeutics's investors?
- Cirius Therapeutics's investors include Frazier Healthcare Partners, Novo Holdings.
- How much funding has Cirius Therapeutics raised?
- Cirius Therapeutics has disclosed $49.6M raised across 6 rounds.
- Where is Cirius Therapeutics headquartered?
- Cirius Therapeutics is headquartered in Grand Rapids, US.